Bio-Rad Labs (BIO) Tops Q1 EPS by 14c; maintains guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
This stock offers one of the most favorable long-term risk/rewards in biotech: RBC
May 8, 2024 4:30 PM EDTRBC Capital analysts highlighted one stock they believe has a favorable risk/reward in a note Wednesday.
The bank continues to view Bio-Rad Labs (NYSE: BIO) as one of the most compelling long-term investment opportunities in its coverage universe, emphasizing a favorable risk/reward profile.
Despite a 25%... More
Bio-Rad Labs (BIO) PT Lowered to $414 at RBC Capital
May 8, 2024 6:22 AM EDTRBC Capital analyst Conor McNamara lowered the price target on Bio-Rad Labs (NYSE: BIO) to $414.00 (from $420.00) while maintaining a Outperform rating.
The analyst comments "We continue to view BIO as one of the most favorable long-term risk/reward names under coverage; though... More
